Polymers polymerized from at least four monomers, and compositions and uses thereof
US-2015353666-A1 · Dec 10, 2015 · US
US9522971B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9522971-B2 |
| Application number | US-201414587617-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 31, 2014 |
| Priority date | Dec 31, 2014 |
| Publication date | Dec 20, 2016 |
| Grant date | Dec 20, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention discloses an amine modifying material which is a copolymer polymerized from an amine functional acrylate, a poly(ethylene glycol) functional acrylate and a cross-linker. The application of the amine modifying material in the bio-molecules separation area is also provided in the present invention.
Opening claim text (preview).
What is claimed is: 1. A copolymer said copolymer being polymerized from [2-(methacryloyloxy)ethyl]trimethylammonium chloride and methoxy poly(ethylene glycol) methacrylate has an average molecular weight between 400 and 600 Daltons and an amine percentage, and said amine percentage of the copolymer is between 30% and 50%. 2. The copolymer according to claim 1 , wherein the methoxy poly(ethylene glycol) methacrylate has an average molecular weight of 500 Daltons. 3. A method for removing leukocytes from a blood sample, said method for removing leukocytes from a blood sample comprising: providing a blood sample containing leukocytes; providing a copolymer, wherein the copolymer being polymerized from an amine functional monomer and a poly(ethylene glycol) functional monomer, wherein the amine functional monomer has the following chemical structure: and wherein the poly(ethylene glycol) functional monomer is selected from one or more of the group consisting of methoxy poly(ethylene glycol) methacrylate and methoxy poly(ethylene glycol) acrylate; and treating the blood sample containing leukocytes with the copolymer, wherein the leukocytes adhere onto the surface of the copolymer so as to remove the leukocytes from the blood sample. 4. The method for removing leukocytes from a blood sample according to claim 3 , wherein the copolymer being polymerized from [2-(methacryloyloxy)ethyl]trimethylammonium chloride and methoxy poly(ethylene glycol) methacrylate has an average molecular weight between 400 and 600 Daltons. 5. The method for removing leukocytes from a blood sample according to claim 1 , wherein the copolymer being polymerized from [2-(methacryloyloxy)ethyl]trimethylammonium chloride and methoxy poly(ethylene glycol) methacrylate has an average molecular weight between 400 and 600 Daltons, and has an amine percentage being between 39% and 50%.
Esters containing nitrogen {, e.g. N,N-dimethylaminoethyl (meth)acrylate} · CPC title
Affinity chromatography or related techniques based upon selective absorption processes · CPC title
Serum albumin, e.g. HSA · CPC title
Fibrinogen · CPC title
Monomers containing two or more (meth)acrylamide groups, e.g. N,N'-methylenebisacrylamide · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.